Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

Medicine

Health & Fitness

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

Share Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Sign up to save your podcasts

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

Retatrutide Before FDA Approval? Lilly Just Changed the Conversation

More shows like On The Pen GLP-1 News

The Hormone Solution | Menopause, Perimenopause, & Women's Midlife Health

Everyday Wellness: Midlife Hormones, Menopause, and Science for Women 35+

The Holistic GLP-1 Podcast with Elizabeth McGann

The Hunter Williams Podcast

The Dr. Tyna Show

Docs Who Lift

The Obesity Guide with Matthea Rentea MD

The Plus SideZ: A GLP-1 Guide to Metabolic Health

Your GLP-1 Bestie

The Peptide Podcast

Fat Science

West Wellness & Longevity

GLP-1 Hub: Support, Community, and Weight Loss

GLP-1 Tribe

Today's discussion